Ano Kaisha no Shikumi
Search
Menu

Fuji Pharma

Fuji Pharma Co.,Ltd.

Company highlights

The annual dividend per share has risen for 4 consecutive years.

Key figures

Period Oct 2024 to Sep 2025ConsolidatedJapanese GAAP

RevenueDisclosed ¥51.7B
Operating marginCalculated 9.7%
Net assets to total assetsCalculated 50.2%

Company profile

Securities code 4554 / EDINET code E00975 / Pharmaceuticals / Fiscal year end September 30

千代田区三番町５番地７／Capital stock ¥3,799 million
Address, capital stock, fiscal year end and industry: the FSA’s EDINET code list.

Official website: https://www.fujipharma.jp/sustainability/esg/social/human-resource-development/
Official website: gBizINFO (Ministry of Economy, Trade and Industry).

Company details
森田 周平 Representative
1 Consolidated subsidiaries

Tables scroll sideways

Disclosed data

Source: Annual Securities Report (Oct 2024 to Sep 2025) · filed 2025-12-18

Profitability ★★★★☆position among all companies 9.7%
Growth (revenue, 4-year average) ★★★★☆position among all companies 11.0%
Capital efficiency ★★☆☆☆position among all companies 6.5%

Business activities and revenue composition

Revenue and profit by business segment

Disclosed segments (business divisions used in reporting): one

Revenue and profit

Fuji Pharma

Period Oct 2024 to Sep 2025Source Annual securities reports

Net sales and operating revenue ¥51.7B　100% Cost of sales ¥30.9B　60% Selling, general and administrative expenses ¥15.8B　31% Operating income ¥5.0B　10%
Amounts by account
GroupAccountAmountConsolidated / Non-consolidated
Selling, general and administrative expenses Other ¥6.4 billion Consolidated
Salaries and bonuses ¥3.8 billion Consolidated
Research and development expenses ¥3.3 billion Consolidated
Depreciation ¥1.4 billion Consolidated
Welfare expenses ¥0.6 billion Parent only
Rent expenses ¥0.6 billion Parent only
Provision for bonuses ¥0.5 billion Consolidated
Traveling and transportation expenses ¥0.5 billion Parent only
Packing and transportation expenses ¥0.5 billion Parent only
Retirement benefit expenses ¥0.2 billion Consolidated
Promotion expenses ¥0.2 billion Parent only
Directors' compensations ¥0.2 billion Parent only
Amortization of goodwill ¥90.00 million Consolidated
Entertainment expenses ¥23.00 million Parent only
Provision for directors' bonuses ¥12.00 million Consolidated
Provision of allowance for doubtful accounts ¥0 Parent only
Profit by stage Gross profit (loss) ¥20.8 billion Consolidated
Operating income ¥5.0 billion Consolidated
Ordinary income ¥4.5 billion Consolidated
Net income ¥3.0 billion Consolidated

Fuji Pharma

Selling, general and administrative expenses

Period Oct 2024 to Sep 2025Source Annual securities reports

Other ¥6.4 billion (39.8%)40%Salaries and bonuses ¥3.8 billion (23.5%)24%Research and development expenses ¥3.3 billion (20.8%)21%Depreciation ¥1.4 billion (8.6%)9%Welfare expenses ¥0.6 billion (3.7%)Rent expenses ¥0.6 billion (3.6%)¥16.1B
  • Other　¥6.4 billion
  • Salaries and bonuses　¥3.8 billion
  • Research and development expenses　¥3.3 billion
  • Depreciation　¥1.4 billion
  • Welfare expenses　¥0.6 billion
  • Rent expenses　¥0.6 billion

Performance, financial position and capital allocation

Finance
50.2% Net assets to total assets Industry median 69.7% FY ending 9/2025 · consolidated / calculated
3.2% Return on assets (ROA)
¥1,917.82 Net assets per share
¥1.6 billion Free cash flow
¥93.4 billion Total assets
Capital allocation
115.7% Cash conversion Industry median 112.1% FY ending 9/2025 · consolidated / calculated
4.9% Increase in working capital ★★★★★ position among all companies FY ending 9/2025 · consolidated / calculated
51.1% Property, plant and equipment purchases relative to depreciation ★★☆☆☆ position among all companies FY ending 9/2025 · consolidated / calculated
17.9% Return to shareholders ★★☆☆☆ position among all companies FY ending 9/2025 · consolidated / calculated
10.9% Investment securities to net assets ★★★☆☆ position among all companies FY ending 9/2025 · consolidated / calculated

Long-term changes in performance

Period 2012 to 2025Disclosed

Revenue ×2.40 from 2012 to 2025

Fuji Pharma

Long-term revenue, profit and asset trends

Period 2012 to 2025Source Annual securities reportsDisclosed

Mark on the chart
52 34 17 0 2012 2014 2016 2018 2020 2022 2024 2025 Net sales and operating revenue Ordinary income 2014　Ordinary income (loss) as a share of revenue -2.5 points 2017　Ordinary income (loss) as a share of revenue +3.6 points 2020　Ordinary income (loss) as a share of revenue -2.7 points 52Latest value 2025 52¥ billion 52Highest in the period shown 2025 52¥ billion 22Lowest in the period shown 2012 22¥ billion ¥ billion

Fuji Pharma

Recent performance trends

Source Annual securities reports

52 34 17 0 4 years ago 3 years ago 2 years ago Last year This year Net sales and operating revenue Ordinary income ¥ billion

Year-on-year comparison

Period 2012 to 2025Disclosed

Item20212022202320242025
Net sales ¥34.0B ¥35.4B ¥40.9B ¥46.1B ¥51.7B
Year on year (%) +0.6% +4.2% +15.4% +12.8% +12.0%
Ordinary income (loss) ¥3.2B ¥3.7B ¥4.5B ¥4.4B ¥4.5B
Change from prior year +9.0% +14.6% +21.3% -1.6% +0.3%
Ordinary income (loss) as a share of Net sales 9.6% 10.5% 11.1% 9.6% 8.6%
Change (percentage points) +0.7 points +1.0 points +0.5 points -1.4 points -1.0 points

Fiscal periods marked for changes

  • 2014Ordinary income (loss) as a share of revenue -2.5 points
  • 2017Ordinary income (loss) as a share of revenue +3.6 points
  • 2020Ordinary income (loss) as a share of revenue -2.7 points

Fuji Pharma

Earnings and net assets per share over time

Unit yenSource Annual securities reports

253 169 84 0 4 years ago 3 years ago 2 years ago Last year This year Earnings per share yen 1,918 1,279 639 0 4 years ago 3 years ago 2 years ago Last year This year Net assets per share yen

Fuji Pharma

Return on equity over time

Unit %Source Annual securities reports

14 9 5 0 4 years ago 3 years ago 2 years ago Last year This year Return on equity (ROE, %)
Consolidated indicators (14 items)
Item4 years ago3 years ago2 years agoLast yearThis year
Net sales ¥34.0 billion ¥35.4 billion ¥40.9 billion ¥46.1 billion ¥51.7 billion
Ordinary income (loss) ¥3.2 billion ¥3.7 billion ¥4.5 billion ¥4.4 billion ¥4.5 billion
Net income (loss) attributable to owners of parent ¥2.4 billion ¥2.7 billion ¥3.4 billion ¥6.1 billion ¥3.0 billion
Comprehensive income ¥2.9 billion ¥3.9 billion ¥6.3 billion ¥5.3 billion ¥2.2 billion
Net assets ¥32.7 billion ¥35.8 billion ¥41.2 billion ¥45.6 billion ¥46.9 billion
Total assets ¥64.2 billion ¥75.5 billion ¥85.3 billion ¥90.0 billion ¥93.4 billion
Net assets per share 1,345.56 yen 1,473.73 yen 1,694.23 yen 1,873.52 yen 1,917.82 yen
Basic earnings (loss) per share 90.54 yen 111.01 yen 141.37 yen 252.85 yen 122.94 yen
Equity-to-asset ratio 50.9% 47.4% 48.3% 50.6% 50.2%
Return on equity 6.7% 7.9% 8.9% 14.2% 6.5%
Net cash provided by (used in) operating activities ¥6.0 billion ¥-0.7 billion ¥1.9 billion ¥4.2 billion ¥5.8 billion
Net cash provided by (used in) investing activities ¥-2.3 billion ¥-11.3 billion ¥-5.2 billion ¥-1.7 billion ¥-4.2 billion
Net cash provided by (used in) financing activities ¥-5.4 billion ¥5.1 billion ¥1.9 billion ¥-0.4 billion ¥1.0 billion
Cash and cash equivalents ¥10.2 billion ¥3.5 billion ¥2.3 billion ¥4.6 billion ¥7.2 billion
Parent only indicators (14 items)
Item4 years ago3 years ago2 years agoLast yearThis year
Net sales ¥31.9 billion ¥32.6 billion ¥37.4 billion ¥41.9 billion ¥47.5 billion
Ordinary income (loss) ¥3.3 billion ¥3.4 billion ¥4.1 billion ¥4.0 billion ¥3.7 billion
Net income (loss) ¥2.6 billion ¥2.5 billion ¥3.1 billion ¥5.8 billion ¥2.5 billion
Capital stock ¥3.8 billion ¥3.8 billion ¥3.8 billion ¥3.8 billion ¥3.9 billion
Total number of issued shares (common stock) 24,753,800 shares 24,753,800 shares 24,753,800 shares 24,753,800 shares 24,891,100 shares
Net assets ¥32.6 billion ¥34.5 billion ¥39.0 billion ¥42.4 billion ¥42.6 billion
Total assets ¥62.1 billion ¥71.3 billion ¥80.0 billion ¥83.7 billion ¥85.7 billion
Net assets per share 1,342.1 yen 1,420.42 yen 1,603.83 yen 1,741.96 yen 1,742.11 yen
Dividend per share 29 yen 35 yen 37 yen 42.5 yen 45.5 yen
Interim dividend per share 14 yen 15 yen 17 yen 20 yen 20 yen
Basic earnings (loss) per share 95.1 yen 102.1 yen 128.27 yen 238.94 yen 100.5 yen
Equity-to-asset ratio 52.5% 48.4% 48.7% 50.6% 49.7%
Return on equity 7.1% 7.4% 8.5% 14.3% 5.8%
Payout ratio 30.5% 34.3% 28.8% 17.8% 45.3%

Dividend history

Source: reporting company’s key figures, annual securities reports · 14 years (2012 to 2025)Parent-onlyDisclosed

4 periods Consecutive increases (own definition) through FY ending 9/2025
7 periods Consecutive periods with dividends (site definition) through FY ending 9/2025
+7.1% Dividend growth (year on year)
+9.4% Dividend growth (5-year annual rate)
Fiscal yearAnnual dividend per share Of which interimPayout ratio (as reported, parent only) Flag
FY ending 9/2025 ¥45.5 ¥20 45.3%
FY ending 9/2024 ¥42.5 ¥20 17.8%
FY ending 9/2023 ¥37 ¥17 28.8%
FY ending 9/2022 ¥35 ¥15 34.3%
FY ending 9/2021 ¥29 ¥14 30.5%
FY ending 9/2020 ¥29 ¥14 44.8%
FY ending 9/2019 ¥29 ¥14 31.2%
FY ending 9/2018 ¥42 ¥28 25.9% Stock split or share consolidation noted
FY ending 9/2017 ¥48 ¥23 22.2%
FY ending 9/2016 ¥45 ¥21 31.4%
FY ending 9/2015 ¥44 ¥20 29.5%
FY ending 9/2014 ¥44 ¥20 29.9%
FY ending 9/2013 ¥40 ¥18 25.2%
FY ending 9/2012 ¥37 ¥18 38.1%

Fuji Pharma

Dividends per share over time

Unit yenSource Annual securities reports

46 30 15 0 4 years ago 3 years ago 2 years ago Last year This year Dividend per share yen

Shareholder composition

As of 2025-09-30Disclosed

Share ownership by holder category

10,785 Shareholders
10.32% Foreign holders (total) Industry median 9.03%
42.56% Individuals and others Industry median 55.96%

Fuji Pharma

Unit %Source Annual securities reports

  • Financial institutions14.73%
  • Securities firms1.80%
  • Other corporations30.59%
  • Foreign holders (institutions)10.22%
  • Foreign holders (individuals)0.10%
  • Individuals and others42.56%

Major shareholders

RankShareholderShareholding ratioShares held
1 有限会社FJP 17.58% 4,307,000
2 今井 博文 12.46% 3,052,000
3 日本マスタートラスト信託銀行株式会社(信託口) 8.81% 2,159,000
4 新井 規子 5.06% 1,240,000
5 Lotus Japan Holdings合同会社 4.98% 1,219,000
6 株式会社日本カストディ銀行(信託口) 4.27% 1,046,000
7 株式会社Yamhill Sciences 4.08% 1,000,000
8 今井 道子 1.82% 446,000
9 公益財団法人今井精一記念財団 1.63% 400,000
10 富士製薬工業従業員持株会 1.52% 372,000

Research and development expenses and capital expenditure

Source: R&D and capital expenditure sections, annual securities reports · 6 years (2015 to 2025)Disclosed

¥3.3 billion Research and development 6.5% of revenue (industry median 14.7%)
¥2.4 billion Capital expenditure 4.6% of revenue (industry median 5.0%)
Fiscal year Research and development Capital expenditure
FY ending 9/2025 ¥3.3 billion ¥2.4 billion
FY ending 9/2024 ¥3.4 billion Could not be retrieved
FY ending 9/2020 ¥3.1 billion ¥3.0 billion
FY ending 9/2019 ¥2.1 billion Could not be retrieved
FY ending 9/2016 ¥1.8 billion Could not be retrieved
FY ending 9/2015 ¥1.7 billion Could not be retrieved

Revenue scale in the same industry

Fuji Pharma

Source Annual securities reports of each company

Pharmaceuticals: 68 companies · revenue · largest first・each company’s latest fiscal year・consolidated (parent-only where no consolidated figures)・Disclosed

Workforce information

Source: Annual Securities Report (Oct 2024 to Sep 2025)Parent-onlyDisclosed

969 Employees (parent only) Industry median 94
43.1 Average age Industry median 44.3
11.0 years Average length of service Industry median 9.6 years
¥6.94 million Average annual salary Industry median ¥8.24 million
People and organisation
29.4¥ million Sales per employee Industry median 38.4¥ million FY ending 9/2025 · consolidated / calculated
¥2.84 million Operating income per employee
67.1% Wage gap between men and women
18.9% Women in managerial positions
64.0% Share of female employees
104.0% Men taking childcare leave
Men 543
Women 426 Employees by gender
3 / 12 Female officers
94 Average temporary staff

Administrative filings and published information

Workplace information filings

Filed 2026-08-27Disclosed

ItemValue
Employees 969
Average monthly overtime (statutory overtime plus work on statutory days off)
Scope: 正社員		 9.8 hours
Annual paid leave taken
Scope: 正社員		 67.3%
Childcare leave taken, men
Scope: 対象とする労働者すべて		 91.7%
Childcare leave taken, women
Scope: 対象とする労働者すべて		 94.4%
Share of managers who are women 18.9%
Share of board members who are women 25%

Greenhouse gas emissions

Reported to the government for fiscal 2023Disclosed

CategoryEmissions
特定事業所排出者13,499 t-CO2
Sites covered by the report1

Audit and disclosure information

Annual securities report, year ended 2025-09-30Disclosed

ItemValue
Audit firm 有限責任あずさ監査法人
Audit fees (this year, total) ¥51.00 million
Non-audit fees (this year, total) Not applicable
Audit fees (this year, network firms) ¥8.00 million
Non-audit fees (this year, network firms) ¥4.00 million
Going concern note Stated as not applicable
Accounting standard Japanese GAAP

See the book series →

Sources and methodology

Retrieved disclosed figures

Accounts and values from the annual securities report, by section

Major management indicators (5 years) (28 items)

ItemValueConsolidated / Non-consolidated
Comprehensive income ¥2.2 billion Consolidated
Net cash provided by (used in) operating activities ¥5.8 billion Consolidated
Net sales ¥51.7 billion Consolidated
Net cash provided by (used in) investing activities ¥-4.2 billion Consolidated
Cash and cash equivalents ¥7.2 billion Consolidated
Net assets ¥46.9 billion Consolidated
Ordinary income (loss) ¥4.5 billion Consolidated
Total assets ¥93.4 billion Consolidated
Return on equity 6.5% Consolidated
Equity-to-asset ratio 50.2% Consolidated
Net income (loss) attributable to owners of parent ¥3.0 billion Consolidated
Net cash provided by (used in) financing activities ¥1.0 billion Consolidated
Basic earnings (loss) per share 122.94 yen Consolidated
Net assets per share 1,917.82 yen Consolidated
Dividend per share 45.5 yen Parent only
Net sales ¥47.5 billion Parent only
Net income (loss) ¥2.5 billion Parent only
Total number of issued shares (common stock) 24,891,100 shares Parent only
Net assets ¥42.6 billion Parent only
Ordinary income (loss) ¥3.7 billion Parent only
Total assets ¥85.7 billion Parent only
Return on equity 5.8% Parent only
Equity-to-asset ratio 49.7% Parent only
Capital stock ¥3.9 billion Parent only
Payout ratio 45.3% Parent only
Interim dividend per share 20 yen Parent only
Basic earnings (loss) per share 100.5 yen Parent only
Net assets per share 1,742.11 yen Parent only

Employees (10 items)

ItemValueConsolidated / Non-consolidated
Number of employees 1,760 people Consolidated
Number of employees 1,760 people Consolidated
Wage gap between men and women (all employees) 67.1% Parent only
Average length of service (years) 11 years Parent only
Average annual salary ¥6.94 million Parent only
Average age (years) 43.1 years old Parent only
Number of employees 969 people Parent only
Number of employees 969 people Parent only
Wage gap between men and women (regular employees) 69.0% Parent only
Wage gap between men and women (non-regular employees) 45.9% Parent only

Shares (12 items)

ItemValueConsolidated / Non-consolidated
Number of shares held 15,243,000 shares Consolidated
Total number of shares held treasury shares etc 395,600 shares Consolidated
Number of shares 24,891,100 shares Consolidated
Shareholding ratio treasury shares etc 1.6% Consolidated
Shareholding ratio 62.2% Consolidated
Number of shares held in own name treasury shares etc 395,600 shares Consolidated
Number of voting rights 244,568 units Consolidated
Carrying amount on the balance sheet ¥10.00 million Consolidated
Carrying amount on the balance sheet ¥5.1 billion Consolidated
Number of issues 3 issues Consolidated
Number of issues 1 issues Consolidated
Total shareholder return 138.9% Parent only

Other disclosed items (6 items)

ItemValueConsolidated / Non-consolidated
Write-downs of inventories ¥-51.00 million Consolidated
Number of consolidated subsidiaries 1 companies Consolidated
Rate of male employees taking childcare leave (all employees) 104.0% Parent only
Average number of temporary employees 94 people Parent only
Total return on the share price index 217.8% Parent only
Ratio of female employees in managerial positions 18.9% Parent only

Research and development (2 items)

ItemValueConsolidated / Non-consolidated
Research and development expenses included in general and administrative expenses and manufacturing cost for current period ¥3.3 billion Consolidated
Research and development expenses ¥3.3 billion Consolidated

Property and facilities (1 items)

ItemValueConsolidated / Non-consolidated
Capital expenditures ¥2.4 billion Consolidated

Audit (7 items)

ItemValueConsolidated / Non-consolidated
Fees for audit and attestation services - reporting company ¥51.00 million Consolidated
Fees for audit and attestation services - total ¥8.00 million Consolidated
Fees for audit and attestation services - total ¥51.00 million Consolidated
Fees for audit and attestation services - consolidated subsidiaries ¥8.00 million Consolidated
Fees for non-audit services - reporting company ¥1.00 million Consolidated
Fees for non-audit services - total ¥4.00 million Consolidated
Non audit fees consolidated subsidiaries network firms ¥2.00 million Consolidated

Balance sheet (154 items)

ItemValueConsolidated / Non-consolidated
Other ¥0.2 billion Consolidated
Other ¥1.4 billion Consolidated
Other ¥2.5 billion Consolidated
Other ¥6.5 billion Consolidated
Other ¥1.1 billion Consolidated
Other ¥0.7 billion Consolidated
Valuation difference on available-for-sale securities ¥-0.5 billion Consolidated
Other, net ¥0.9 billion Consolidated
Lease obligations ¥4.1 billion Consolidated
Lease obligations ¥0.6 billion Consolidated
Lease assets ¥5.9 billion Consolidated
Lease assets, net ¥4.3 billion Consolidated
Work in process ¥3.2 billion Consolidated
Retained earnings ¥36.2 billion Consolidated
Advance payments trade ¥35.00 million Consolidated
Raw materials and supplies ¥11.4 billion Consolidated
Notes receivable - trade ¥3.2 billion Consolidated
Merchandise and finished goods ¥6.6 billion Consolidated
Non-current liabilities ¥15.5 billion Consolidated
Non-current assets ¥45.5 billion Consolidated
Land ¥1.3 billion Consolidated
Accounts receivable - trade ¥14.7 billion Consolidated
Buildings and structures ¥18.6 billion Consolidated
Buildings and structures, net ¥9.5 billion Consolidated
Construction in progress ¥0.9 billion Consolidated
Provision for directors' bonuses ¥12.00 million Consolidated
Investments and other assets ¥10.6 billion Consolidated
Investment securities ¥5.1 billion Consolidated
Notes and accounts payable - trade ¥4.6 billion Consolidated
Subscription rights to shares ¥3.00 million Consolidated
Property, plant and equipment ¥20.9 billion Consolidated
Accounts receivable - other ¥0.3 billion Consolidated
Income taxes payable ¥1.0 billion Consolidated
Shareholders' equity ¥44.1 billion Consolidated
Machinery, equipment and vehicles ¥15.1 billion Consolidated
Machinery, equipment and vehicles, net ¥4.0 billion Consolidated
Current liabilities ¥31.0 billion Consolidated
Current assets ¥47.9 billion Consolidated
Accumulated depreciation ¥-1.6 billion Consolidated
Accumulated depreciation ¥-1.6 billion Consolidated
Accumulated depreciation ¥-9.0 billion Consolidated
Accumulated depreciation ¥-11.1 billion Consolidated
Foreign currency translation adjustment ¥3.1 billion Consolidated
Intangible assets ¥13.9 billion Consolidated
Cash and cash equivalents ¥7.2 billion Consolidated
Cash and deposits ¥7.2 billion Consolidated
Short-term loans payable ¥15.3 billion Consolidated
Bonds payable ¥1.8 billion Consolidated
Net assets ¥46.9 billion Consolidated
Net assets ¥46.9 billion Consolidated
Total assets ¥93.4 billion Consolidated
Deferred gains or losses on hedges ¥16.00 million Consolidated
Deferred tax assets ¥2.3 billion Consolidated
Treasury stock ¥-0.5 billion Consolidated
Valuation and translation adjustments ¥2.8 billion Consolidated
Liabilities ¥46.5 billion Consolidated
Liabilities and net assets ¥93.4 billion Consolidated
Allowance for doubtful accounts ¥-0 Consolidated
Capital surplus ¥4.5 billion Consolidated
Capital stock ¥3.9 billion Consolidated
Provision for bonuses ¥1.1 billion Consolidated
Remeasurements of defined benefit plans ¥0.1 billion Consolidated
Net defined benefit liability ¥2.2 billion Consolidated
Long-term loans payable ¥7.2 billion Consolidated
Non-controlling interests ¥3.00 million Consolidated
Current portion of bonds payable ¥0.7 billion Consolidated
Current portion of long-term loans payable ¥1.3 billion Consolidated
Other ¥0.3 billion Parent only
Other ¥0.4 billion Parent only
Other ¥0.4 billion Parent only
Valuation difference on available-for-sale securities ¥-0.5 billion Parent only
Other capital surplus ¥4.4 billion Parent only
Software ¥0.6 billion Parent only
Lease obligations ¥4.1 billion Parent only
Lease obligations ¥0.6 billion Parent only
Lease assets ¥5.9 billion Parent only
Lease assets, net ¥4.3 billion Parent only
Work in process ¥3.0 billion Parent only
Investments in capital ¥0 Parent only
General reserve ¥5.0 billion Parent only
Retained earnings ¥35.2 billion Parent only
Legal retained earnings ¥0.5 billion Parent only
Advances received ¥0.2 billion Parent only
Prepaid expenses ¥0.3 billion Parent only
Advance payments trade ¥4.00 million Parent only
Raw materials and supplies ¥8.6 billion Parent only
Guarantee deposits received ¥77.00 million Parent only
Notes receivable - trade ¥3.2 billion Parent only
Merchandise and finished goods ¥5.9 billion Parent only
Right of trademark ¥0 Parent only
Non-current liabilities ¥14.9 billion Parent only
Non-current assets ¥44.4 billion Parent only
Land ¥0.8 billion Parent only
Accounts receivable - trade ¥13.3 billion Parent only
Tools, furniture and fixtures ¥2.1 billion Parent only
Tools, furniture and fixtures ¥0.7 billion Parent only
Buildings ¥13.5 billion Parent only
Buildings, net ¥7.5 billion Parent only
Construction in progress ¥0.4 billion Parent only
Provision for directors' bonuses ¥12.00 million Parent only
Investments and other assets ¥16.5 billion Parent only
Investment securities ¥5.1 billion Parent only
Notes payable trade ¥0.2 billion Parent only
Subscription rights to shares ¥3.00 million Parent only
Property, plant and equipment ¥15.6 billion Parent only
Accounts receivable - other ¥0.3 billion Parent only
Income taxes payable ¥1.0 billion Parent only
Accrued expenses ¥1.3 billion Parent only
Accounts payable - other ¥3.2 billion Parent only
Shareholders' equity ¥43.1 billion Parent only
Structures ¥0.5 billion Parent only
Structures, net ¥0.2 billion Parent only
Machinery and equipment ¥6.7 billion Parent only
Machinery and equipment, net ¥1.6 billion Parent only
Current liabilities ¥28.1 billion Parent only
Current assets ¥41.2 billion Parent only
Accumulated depreciation ¥-1.6 billion Parent only
Accumulated depreciation ¥-1.3 billion Parent only
Accumulated depreciation ¥-6.0 billion Parent only
Accumulated depreciation ¥-0.3 billion Parent only
Accumulated depreciation ¥-5.0 billion Parent only
Accumulated depreciation ¥-60.00 million Parent only
Intangible assets ¥12.3 billion Parent only
Cash and deposits ¥5.4 billion Parent only
Short-term loans payable ¥15.3 billion Parent only
Bonds payable ¥1.8 billion Parent only
Net assets ¥42.6 billion Parent only
Net assets ¥42.6 billion Parent only
Total assets ¥85.7 billion Parent only
Deferred gains or losses on hedges ¥16.00 million Parent only
Deferred tax assets ¥2.2 billion Parent only
Retained earnings brought forward ¥29.7 billion Parent only
Treasury stock ¥-0.5 billion Parent only
Valuation and translation adjustments ¥-0.5 billion Parent only
Liabilities ¥43.1 billion Parent only
Liabilities and net assets ¥85.7 billion Parent only
Accounts payable - trade ¥2.8 billion Parent only
Allowance for doubtful accounts ¥-0 Parent only
Capital surplus ¥4.5 billion Parent only
Legal capital surplus ¥0.1 billion Parent only
Capital stock ¥3.9 billion Parent only
Provision for bonuses ¥1.1 billion Parent only
Vehicle and delivery equipment ¥72.00 million Parent only
Vehicles, net ¥12.00 million Parent only
Provision for retirement benefits ¥1.6 billion Parent only
Long-term loans payable ¥7.2 billion Parent only
Long-term prepaid expenses ¥1.1 billion Parent only
Long term accounts payable other ¥0.1 billion Parent only
Shares of subsidiaries and associates ¥6.0 billion Parent only
Loans receivable to subsidiaries and affiliates ¥0.7 billion Parent only
Telephone subscription right ¥7.00 million Parent only
Deposits received ¥90.00 million Parent only
Current portion of bonds payable ¥0.7 billion Parent only
Current portion of long-term loans payable ¥1.3 billion Parent only

Accounts unique to this company (8 items)

ItemValueConsolidated / Non-consolidated
Revenue ¥13.3 billion Consolidated
Revenue ¥1.8 billion Consolidated
Revenue ¥0.3 billion Consolidated
Revenue ¥-0.5 billion Consolidated
Revenue ¥11.7 billion Parent only
Revenue ¥1.8 billion Parent only
Revenue ¥1.5 billion Parent only
Revenue ¥0.3 billion Parent only

Statement of income (107 items)

ItemValueConsolidated / Non-consolidated
Other ¥40.00 million Consolidated
Other ¥65.00 million Consolidated
Other ¥6.4 billion Consolidated
Other comprehensive income ¥-0.8 billion Consolidated
Valuation difference on available for sale securities net of tax ¥-1.4 billion Consolidated
Amortization of goodwill ¥90.00 million Consolidated
Loss on valuation of derivatives ¥0.3 billion Consolidated
Dividends from surplus ¥-1.0 billion Consolidated
Subsidy income ¥69.00 million Consolidated
Comprehensive income ¥2.2 billion Consolidated
Insurance ¥42.00 million Consolidated
Operating income ¥5.0 billion Consolidated
Non-operating income ¥0.2 billion Consolidated
Non-operating expenses ¥0.7 billion Consolidated
Net cash provided by (used in) operating activities ¥5.8 billion Consolidated
Loss on tax purpose reduction entry of non-current assets ¥60.00 million Consolidated
Cost of sales ¥30.9 billion Consolidated
Gross profit (loss) ¥20.8 billion Consolidated
Net sales ¥51.7 billion Consolidated
Net income ¥3.0 billion Consolidated
Net income ¥3.0 billion Consolidated
Net income (loss) ¥3.0 billion Consolidated
Net income (loss) ¥3.0 billion Consolidated
Provision for directors' bonuses ¥12.00 million Consolidated
Net cash provided by (used in) investing activities ¥-4.2 billion Consolidated
Interest expenses ¥0.3 billion Consolidated
Issuance of new shares ¥0.2 billion Consolidated
Income taxes - current ¥1.3 billion Consolidated
Income taxes ¥1.0 billion Consolidated
Income taxes - deferred ¥-0.6 billion Consolidated
Depreciation ¥1.4 billion Consolidated
Impairment loss ¥0.4 billion Consolidated
Loss on disaster ¥3.00 million Consolidated
Foreign exchange gains ¥35.00 million Consolidated
Foreign currency translation adjustment net of tax ¥0.5 billion Consolidated
Extraordinary loss ¥0.5 billion Consolidated
Effect of exchange rate change on cash and cash equivalents ¥0.1 billion Consolidated
Net increase (decrease) in cash and cash equivalents ¥2.7 billion Consolidated
Research and development expenses ¥3.3 billion Consolidated
Income (loss) before income taxes ¥4.0 billion Consolidated
Income (loss) before income taxes ¥4.0 billion Consolidated
Ordinary income ¥4.5 billion Consolidated
Salaries and bonuses ¥3.8 billion Consolidated
Deferred gains or losses on hedges net of tax ¥6.00 million Consolidated
Disposal of treasury stock ¥6.00 million Consolidated
Purchase of treasury stock ¥-0 Consolidated
Comprehensive income attributable to owners of parent ¥2.2 billion Consolidated
Net cash provided by (used in) financing activities ¥1.0 billion Consolidated
Selling, general and administrative expenses ¥15.8 billion Consolidated
Provision for bonuses ¥0.5 billion Consolidated
Remeasurements of defined benefit plans net of tax ¥80.00 million Consolidated
Retirement benefit expenses ¥0.2 billion Consolidated
Comprehensive income attributable to non-controlling interests ¥0 Consolidated
Net income (loss) attributable to non-controlling interests ¥0 Consolidated
Other ¥43.00 million Parent only
Other ¥65.00 million Parent only
Other ¥3.2 billion Parent only
Loss on valuation of derivatives ¥0.3 billion Parent only
Entertainment expenses ¥23.00 million Parent only
Transfer from other account cos ¥-0.2 billion Parent only
Transfer to other accounts ¥0.2 billion Parent only
Dividends from surplus ¥-1.0 billion Parent only
Subsidy income ¥69.00 million Parent only
Insurance ¥42.00 million Parent only
Total ¥35.1 billion Parent only
Ending merchandise and finished goods ¥5.9 billion Parent only
Beginning merchandise and finished goods ¥4.9 billion Parent only
Merchandize sales ¥2.9 billion Parent only
Operating income ¥4.2 billion Parent only
Non-operating income ¥0.2 billion Parent only
Non-operating expenses ¥0.7 billion Parent only
Loss on tax purpose reduction entry of non-current assets ¥60.00 million Parent only
Cost of sales ¥29.0 billion Parent only
Gross profit (loss) ¥18.5 billion Parent only
Net sales ¥47.5 billion Parent only
Cost of purchased goods ¥2.1 billion Parent only
Net income (loss) ¥2.5 billion Parent only
Net income (loss) ¥2.5 billion Parent only
Cost of products manufactured ¥26.7 billion Parent only
Directors' compensations ¥0.2 billion Parent only
Provision for directors' bonuses ¥12.00 million Parent only
Interest expenses ¥0.3 billion Parent only
Issuance of new shares ¥0.2 billion Parent only
Traveling and transportation expenses ¥0.5 billion Parent only
Income taxes - current ¥1.1 billion Parent only
Income taxes ¥0.8 billion Parent only
Income taxes - deferred ¥-0.6 billion Parent only
Depreciation ¥1.3 billion Parent only
Impairment loss ¥0.4 billion Parent only
Loss on disaster ¥3.00 million Parent only
Foreign exchange gains ¥58.00 million Parent only
Extraordinary loss ¥0.5 billion Parent only
Research and development expenses ¥3.3 billion Parent only
Welfare expenses ¥0.6 billion Parent only
Income (loss) before income taxes ¥3.2 billion Parent only
Ordinary income ¥3.7 billion Parent only
Salaries and bonuses ¥3.2 billion Parent only
Disposal of treasury stock ¥6.00 million Parent only
Purchase of treasury stock ¥-0 Parent only
Packing and transportation expenses ¥0.5 billion Parent only
Product sales revenue ¥44.6 billion Parent only
Promotion expenses ¥0.2 billion Parent only
Selling, general and administrative expenses ¥14.3 billion Parent only
Provision of allowance for doubtful accounts ¥0 Parent only
Rent expenses ¥0.6 billion Parent only
Provision for bonuses ¥0.5 billion Parent only
Retirement benefit expenses ¥0.1 billion Parent only

Statement of changes in equity (4 items)

ItemValueConsolidated / Non-consolidated
Total changes during the period ¥1.3 billion Consolidated
Net changes in items other than shareholders' equity ¥-0.8 billion Consolidated
Total changes during the period ¥0.2 billion Parent only
Net changes in items other than shareholders' equity ¥-1.4 billion Parent only

Statement of cash flows (31 items)

ItemValueConsolidated / Non-consolidated
Other ¥0.9 billion Consolidated
Other ¥0.1 billion Consolidated
Other ¥-6.00 million Consolidated
Amortization of goodwill ¥90.00 million Consolidated
Loss gain on valuation of derivatives ¥0.3 billion Consolidated
Repayments of lease obligations ¥-0.5 billion Consolidated
Increase decrease in notes and accounts payable trade ¥0.4 billion Consolidated
Interest expenses paid ¥-0.3 billion Consolidated
Interest and dividends income received ¥5.00 million Consolidated
Interest and dividend income ¥-5.00 million Consolidated
Decrease increase in notes and accounts receivable trade ¥0.5 billion Consolidated
Subtotal ¥8.3 billion Consolidated
Increase decrease in provision for directors bonuses ¥3.00 million Consolidated
Interest expenses ¥0.3 billion Consolidated
Proceeds from exercise of share acquisition rights ¥0.2 billion Consolidated
Purchase of property plant and equipment ¥-2.0 billion Consolidated
Proceeds from sales of property plant and equipment ¥2.00 million Consolidated
Decrease (increase) in inventories ¥-3.1 billion Consolidated
Income taxes paid ¥-2.2 billion Consolidated
Depreciation ¥3.9 billion Consolidated
Impairment loss ¥0.4 billion Consolidated
Foreign exchange loss (gain) ¥-51.00 million Consolidated
Purchase of intangible assets ¥-1.9 billion Consolidated
Redemption of bonds ¥-0.7 billion Consolidated
Proceeds from issuance of bonds ¥1.0 billion Consolidated
Increase (decrease) in allowance for doubtful accounts ¥0 Consolidated
Increase (decrease) in provision for bonuses ¥0.5 billion Consolidated
Increase (decrease) in net defined benefit liability ¥0.1 billion Consolidated
Dividends ¥-1.0 billion Consolidated
Proceeds from long term loans payable ¥9.0 billion Consolidated
Repayment of long term loans payable ¥-7.1 billion Consolidated
Basic indicators
ItemValueConsolidated / Non-consolidatedSource
Net cash provided by (used in) operating activities ¥5.8 billion ConsolidatedDisclosed
Dividend per share 46 Parent onlyDisclosed
Number of employees 1,760 ConsolidatedDisclosed
Net assets ¥46.9 billion ConsolidatedDisclosed
Net sales ¥51.7 billion ConsolidatedDisclosed
Operating income ¥5.0 billion ConsolidatedDisclosed
Ordinary income ¥4.5 billion ConsolidatedDisclosed
Net income ¥3.0 billion ConsolidatedDisclosed
Total assets ¥93.4 billion ConsolidatedDisclosed
Operating margin 9.7%ConsolidatedCalculated
Net margin 5.8%ConsolidatedCalculated
Sales per employee 29361932 yenConsolidatedCalculated
Total asset turnover 0.55 timesConsolidatedCalculated
Net assets to total assets 50.2%ConsolidatedCalculated
How to read the figures, and caveats

Terms

  • Consolidated: the parent company together with the subsidiaries it consolidates
  • Parent-only: the single company that filed the annual securities report
  • Calculated: a disclosed figure put through the formula shown
  • Not disclosed: no such value in the filing (not treated as zero)
  • Not retrieved: a value this page could not extract, including values in the filing that could not be matched. The same item may appear in another table
  • Segment: a business division the company uses in its disclosures
  • Industry median: the middle value among companies in the same industry that disclose the item
  • ★: position when every company is lined up by value (not a judgement of the company)See the formulas
  • Source: document name, period covered, filing date and where it was obtained
  • Tables scroll sideways

Key figures

  • Operating margin 9.7%　Operating income ÷ net sales 　＝ ¥5.0 billion ÷ ¥51.7 billion
    Operating income ÷ net sales. The denominator is Net sales (Consolidated, Japanese GAAP).
  • Net margin 5.8%　Net income ÷ net sales 　＝ ¥3.0 billion ÷ ¥51.7 billion
    Net income ÷ net sales. The denominator is Net sales (Consolidated, Japanese GAAP).
  • Sales per employee 29,361,932 yen　Sales or operating revenue ÷ employees 　＝ ¥51.7 billion ÷ 1,760 people
    Sales or operating revenue ÷ employees. The denominator is Number of employees (Consolidated, Japanese GAAP).
  • Total asset turnover 0.55 times　Sales or operating revenue ÷ total assets 　＝ ¥51.7 billion ÷ ¥93.4 billion
    Sales or operating revenue ÷ total assets. The denominator is Total assets (Consolidated, Japanese GAAP).
  • Net assets to total assets 50.2%　Net assets ÷ total assets 　＝ ¥46.9 billion ÷ ¥93.4 billion
    Net assets ÷ total assets. The denominator is Total assets (Consolidated, Japanese GAAP).

Company details

  • Representative　President, Representative Director, gBizINFO
  • Consolidated subsidiaries　Annual Securities Report

Amounts by account

  • Totals and their component lines together; consolidated and parent-only figures mixed (right-hand column)

Selling, general and administrative expenses

  • Breakdown of selling, general and administrative expenses (costs of selling and running the company). Cost of sales not included
  • Each item: already inside the SG&A total (not added to it)

Finance

  • Net assets to total assets　Net assets ÷ total assets
  • Return on assets (ROA)　Net income ÷ total assets (consolidated)
  • Net assets per share　Consolidated
  • Free cash flow　Free cash flow: operating cash flow (cash generated by the business) plus investing cash flow (asset purchases, disposals and other investments), consolidated
  • Total assets　Consolidated

Capital allocation

  • ★: position when all companies are sorted by value and cut into fifths (a position, not a rating). The five items with ★: only where both numerator and denominator are available on a consolidated basisSee the formulas
  • Cash conversion　Net cash provided by (used in) operating activities ÷ operating income
  • Increase in working capital　(increase in trade receivables + increase in inventories) ÷ net sales (or operating revenue)。Trade receivables down ¥0.5 billion + inventories up ¥3.1 billion, over net sales ¥51.7 billion
  • Property, plant and equipment purchases relative to depreciation　Purchase of property, plant and equipment ÷ depreciation。Purchase of property, plant and equipment ¥2.0 billion, over depreciation ¥3.9 billion
  • Return to shareholders　(dividends paid + purchase of treasury stock) ÷ net cash provided by operating activities。Dividends paid ¥1.0 billion (no treasury stock purchase disclosed), over operating cash flow ¥5.8 billion
  • Investment securities to net assets　Investment securities ÷ net assets。Investment securities ¥5.1 billion, over net assets ¥46.9 billion

Long-term changes in performance

  • Revenue　Disclosed value for 2025 ÷ disclosed value for 2012

Year-on-year comparison

  • Year on year: calculated only where the item, reporting range and accounting standard match and the periods are consecutive
  • Comparison basis not confirmed: periods with a change of accounting standard or reporting range, a moved fiscal year end, or an unconfirmed period
  • ◆: a period where revenue moved 20% or more from the prior year, profit as a share of revenue moved 2.0 percentage points or more, or profit or loss changed sign. Item used named in the table and list. Not a ranking of companies

Earnings and net assets per share over time

  • Earnings per share = net profit ÷ shares; net assets per share = net assets ÷ shares. Disclosed values from the key financial indicators of the annual securities report. No share prices used

Return on equity over time

  • Return on equity (ROE): net profit as a proportion of equity. For Japanese companies, the disclosed value in the key financial indicators of the annual securities report (decimals converted to percentages)

Dividend history

  • Payout ratio: dividends as a proportion of net profit. Dividend amounts and payout ratios: the reporting company’s parent-only disclosed values (as written in the annual securities report, not recalculated from consolidated profit). Consecutive increases: years in a row, from the latest backwards, in which the annual dividend per share rose. Consecutive years with a dividend: years in a row with an annual dividend per share above zero. Both this site’s own count (not the criteria of any published index). A year with no disclosure not read as zero; counting stops there. Range limited to the years listed above. Flagged 1 years: a note about a stock split or share consolidation, or a period other than 12 months. No calculation across those years, as the dividend per share may rest on a different share base.

Share ownership by holder category

  • Source: ownership table, annual securities report. Percentages as disclosed, calculated on trading units (some companies do not total exactly 100%). Foreign holders (total): institutions and individuals combined. “Individuals and others”: a register category (not necessarily the share actually held by individuals). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Major shareholders

  • Source: major shareholders table, annual securities report. Trust bank holdings as written (whose trust is not disclosed)

Research and development expenses and capital expenditure

  • Research and development: total in the R&D section of the annual securities report. Capital expenditure: this year’s actual spending in the capital expenditure overview (not a plan). Years: only those available in the annual securities reports on hand (one to four per company); no row for other years. Share of revenue: divided by consolidated revenue in the same annual securities report. Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Revenue scale in the same industry

  • Revenue (disclosed values) of companies in the same industry, using the same grouping as the industry pages. Only the top three and the two companies either side of this one. Bar length relative to the largest company (100). An order of size, not a ranking of quality

Workforce information

  • All four: the reporting company (parent-only), as disclosed in the employee section of the annual securities report. Employees across the consolidated group: 1,760 (a different scope, kept apart from the four above). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

People and organisation

  • Sales per employee　Net sales (or operating revenue) ÷ employees
  • Operating income per employee　Operating income ÷ employees
  • Wage gap between men and women　Women's pay with men's pay set to 100, reporting company
  • Women in managerial positions　Reporting company (parent only)
  • Share of female employees　gBizINFO, covering その他
  • Men taking childcare leave　Reporting company (parent only)
  • Employees by gender　gBizINFO
  • Female officers　gBizINFO: 3 women among 12 officers
  • Average temporary staff　Parent only, average headcount other than regular employees

Workplace information filings

  • Source: processed from Shokuba-labo, the workplace information site of the Ministry of Health, Labour and Welfare. Items the company filed only Shokuba-labo

Greenhouse gas emissions

  • Source: processed from the Ministry of the Environment’s greenhouse gas calculation, reporting and disclosure system (EEGS). Companies required to report only Ministry of the Environment (EEGS)

Audit and disclosure information

  • Whether there is a going concern note (the accounting assumption that a company will continue operating), and audit information
  • Audit firm, audit fees, going concern note and accounting standard: facts written in the latest annual securities report and the audit report filed with it (not a judgement of the company). Going concern note: “note” when the note text is present, “not applicable” when the report states nothing to report, “cannot be determined” when neither appears. Note text not reproduced. Amended filings not shown (annual securities reports only)

Data sources and calculation methods

Primary source: the annual securities report of Fuji Pharma Co.,Ltd. on EDINET, the FSA’s disclosure system (free to read)
Corporate number: 5010001084045 / Accounting standard: Japanese GAAP

  • Amounts: machine transcription of EDINET XBRL (no manual re-keying). Long narrative notes are text and not in the account list. Identifiers: machine transcription of the EDINET code list (retrieved 2026-08-22)
  • ★: position of the value calculated from disclosed figures among the 4,240 companies on this site, on a five-step scale. Not a judgement of the company. No forecasts usedThe formulas and how they are counted
  • No rank: net assets as a share of total assets, cash conversion and revenue per employee (size alone does not show quality). Industry median shown for comparison. Cash conversion of 100%: operating cash flow equal to operating profit
  • Profit-and-loss chart: only where “sales − cost of sales − SG&A = operating income” holds between disclosed values. Cost breakdown: the six largest SG&A items
  • Trend charts: key financial indicators of the annual securities report. Amounts in billions of yen (dividend per share in yen). Long-run chart joins reports filed in different years (newer report for overlapping years). Some items stop part-way after a change of accounting standard. A stock split changes the weight of one share. Consolidated and parent-only in separate tables
  • Revenue scale in the same industry: bars of revenue (disclosed values) of companies in the same industry grouping as the industry pages, largest first. Only the top three and the two companies either side of this one. Each company’s latest fiscal year. An order of size, not a ranking of quality or an investment view
  • Share prices: not published (no data source allows redistribution). No share-price-based indicators (such as the price earnings ratio) and no extension of past growth into the future
  • Average age, average length of service and average annual salary: the reporting company alone (the parent). At a holding company, a small head-office staff. Payout ratio (basic facts): dividend per share ÷ consolidated earnings per share, calculated here (the payout ratio in the annual securities report is the reporting company’s figure, on a different basis). Representative and founding date: gBizINFO (Ministry of Economy, Trade and Industry), some companies only
  • “Retrieved disclosed figures”: every value readable as a number from the annual securities report. Company-wide values only (no segment or other breakdowns)
  • Segment table: machine transcription of the segment information in the annual securities report. Business names as labelled by the company in its XBRL. No table where segment sales differ from the disclosed total by more than 1%. Adjustments, corporate, eliminations and “other” left out of the table and the share denominator, as they are not businesses
  • Breakdowns of amounts, not diagrams of how the business works. Who pays whom, and for what, is not in the disclosed figures; no lines drawn from guesswork